(Q39686121)

14 September 2017

In vitro activity of telavancin against resistant gram-positive bacteria (English)

1 reference

14 September 2017

gram-positive bacteria

0 references

3

Stacey Difuntorum

0 references

author name string

Kevin M Krause

1

1 reference

14 September 2017

Marika Renelli

2

1 reference

14 September 2017

Terry X Wu

4

1 reference

14 September 2017

Dmitri V Debabov

5

1 reference

14 September 2017

Bret M Benton

6

1 reference

14 September 2017

language of work or name

English

0 references

publication date

28 April 2008

1 reference

Antimicrobial Agents and Chemotherapy

14 September 2017

1 reference

14 September 2017

52

1 reference

14 September 2017

7

1 reference

14 September 2017

2647-2652

1 reference

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Antimicrobial resistance: the example of Staphylococcus aureus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

The emergence and evolution of methicillin-resistant Staphylococcus aureus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

In vitro activity of TD-6424 against Staphylococcus aureus

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Antimicrobial resistance in staphylococci. Epidemiology, molecular mechanisms, and clinical relevance

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Gram-positive resistance: challenge for the development of new antibiotics

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2443888

Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18443122

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01398-07

1 reference

release_fg37eot4j5f7dhpvy6ovj3v6u4

14 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fg37eot4j5f7dhpvy6ovj3v6u4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

14 September 2017

PubMed publication ID

18443122

1 reference